PMID- 28277320
OWN - NLM
STAT- MEDLINE
DCOM- 20170814
LR  - 20240326
IS  - 1526-7598 (Electronic)
IS  - 0003-2999 (Print)
IS  - 0003-2999 (Linking)
VI  - 124
IP  - 6
DP  - 2017 Jun
TI  - Subcellular Energetics and Metabolism: Potential Therapeutic Applications.
PG  - 1872-1885
LID - 10.1213/ANE.0000000000001865 [doi]
AB  - Part I of this review discussed the similarities between embryogenesis, mammalian 
      adaptions to hypoxia (primarily driven by hypoxia-inducible factor-1 [HIF-1]), 
      ischemia-reperfusion injury (and its relationship with reactive oxygen species), 
      hibernation, diving animals, cancer, and sepsis, and it focused on the common 
      characteristics that allow cells and organisms to survive in these states. Part 
      II of this review describes techniques by which researchers gain insight into 
      subcellular energetics and identify potential future tools for clinicians. In 
      particular, P nuclear magnetic resonance to measure high-energy phosphates, serum 
      lactate measurements, the use of near-infrared spectroscopy to measure the 
      oxidation state of cytochrome aa3, and the ability of the protoporphyrin 
      IX-triplet state lifetime technique to measure mitochondrial oxygen tension are 
      discussed. In addition, this review discusses novel treatment strategies such as 
      hyperbaric oxygen, preconditioning, exercise training, therapeutic gases, as well 
      as inhibitors of HIF-1, HIF prolyl hydroxylase, and peroxisome 
      proliferator-activated receptors.
FAU - Thiele, Robert H
AU  - Thiele RH
AD  - From the Department of Anesthesiology, University of Virginia, Charlottesville, 
      Virginia.
LA  - eng
GR  - K08 GM115861/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Biomarkers)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Gases)
RN  - 0 (Hypoxia-Inducible Factor 1)
RN  - 0 (Peroxisome Proliferator-Activated Receptors)
RN  - 0 (Protective Agents)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 7U1EE4V452 (Carbon Monoxide)
RN  - EC 1.14.11.29 (Hypoxia-Inducible Factor-Proline Dioxygenases)
RN  - S88TT14065 (Oxygen)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Adaptation, Physiological
MH  - Animals
MH  - Biomarkers/blood
MH  - Carbon Monoxide/therapeutic use
MH  - Cell Hypoxia
MH  - Cellular Microenvironment
MH  - *Energy Metabolism/drug effects
MH  - Enzyme Inhibitors/therapeutic use
MH  - *Exercise Therapy
MH  - Gases
MH  - Humans
MH  - Hydrogen Sulfide/therapeutic use
MH  - *Hyperbaric Oxygenation
MH  - Hypoxia-Inducible Factor 1/antagonists & inhibitors/metabolism
MH  - Hypoxia-Inducible Factor-Proline Dioxygenases/antagonists & inhibitors/metabolism
MH  - Magnetic Resonance Spectroscopy/methods
MH  - Nitric Oxide/therapeutic use
MH  - Oxygen/*metabolism/*therapeutic use
MH  - Peroxisome Proliferator-Activated Receptors/agonists/metabolism
MH  - Protective Agents/metabolism/*therapeutic use
MH  - *Signal Transduction/drug effects
MH  - Spectroscopy, Near-Infrared
PMC - PMC5438276
MID - NIHMS841714
COIS- Conflicts: Robert H. Thiele reported no conflicts of interest
EDAT- 2017/03/10 06:00
MHDA- 2017/08/15 06:00
PMCR- 2018/06/01
CRDT- 2017/03/10 06:00
PHST- 2017/03/10 06:00 [pubmed]
PHST- 2017/08/15 06:00 [medline]
PHST- 2017/03/10 06:00 [entrez]
PHST- 2018/06/01 00:00 [pmc-release]
AID - 10.1213/ANE.0000000000001865 [doi]
PST - ppublish
SO  - Anesth Analg. 2017 Jun;124(6):1872-1885. doi: 10.1213/ANE.0000000000001865.